Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.91 $2.42 Friday, 10th May 2024 CANF stock ended at $2.09. This is 2.42% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 3.29% from a day low at $2.05 to a day high of $2.12.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
May 31, 2016 $2.73 $2.89 $2.73 $2.87 45 700
May 27, 2016 $2.82 $2.85 $2.72 $2.79 37 500
May 26, 2016 $2.69 $2.88 $2.60 $2.77 105 300
May 25, 2016 $2.78 $2.93 $2.70 $2.70 106 800
May 24, 2016 $2.68 $2.94 $2.68 $2.81 302 700
May 23, 2016 $2.73 $2.76 $2.61 $2.76 49 900
May 20, 2016 $2.50 $2.66 $2.50 $2.64 166 500
May 19, 2016 $2.56 $2.61 $2.51 $2.51 41 200
May 18, 2016 $2.55 $2.71 $2.55 $2.62 54 300
May 17, 2016 $2.68 $2.68 $2.55 $2.63 63 300
May 16, 2016 $2.58 $2.65 $2.58 $2.63 43 100
May 13, 2016 $2.41 $2.60 $2.41 $2.55 37 200
May 12, 2016 $2.67 $2.67 $2.50 $2.54 121 600
May 11, 2016 $2.75 $2.82 $2.61 $2.70 24 700
May 10, 2016 $2.80 $2.80 $2.65 $2.75 40 600
May 09, 2016 $2.74 $2.78 $2.65 $2.74 70 400
May 06, 2016 $2.58 $2.75 $2.58 $2.73 52 500
May 05, 2016 $2.62 $2.79 $2.60 $2.60 83 600
May 04, 2016 $2.80 $2.89 $2.62 $2.63 107 700
May 03, 2016 $2.80 $2.90 $2.80 $2.83 49 200
May 02, 2016 $2.98 $2.98 $2.84 $2.90 63 100
Apr 29, 2016 $2.84 $2.92 $2.84 $2.84 58 900
Apr 28, 2016 $2.91 $2.97 $2.88 $2.89 37 600
Apr 27, 2016 $3.06 $3.06 $2.85 $2.91 127 300
Apr 26, 2016 $2.96 $3.08 $2.90 $3.04 90 400
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT